Cytosorbents Crp - Asset Resilience Ratio
Cytosorbents Crp (CTSO) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Cytosorbents Crp's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2017)
This chart shows how Cytosorbents Crp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cytosorbents Crp total assets.
Liquid Assets Composition Over Time
This chart breaks down Cytosorbents Crp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Cytosorbents Crp (CTSO) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Cytosorbents Crp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Cytosorbents Crp Industry Peers by Asset Resilience Ratio
Compare Cytosorbents Crp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Cytosorbents Crp (2008–2017)
The table below shows the annual Asset Resilience Ratio data for Cytosorbents Crp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $24.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $9.69 Million | -- |
| 2015-12-31 | 19.48% | $2.19 Million | $11.25 Million | -3.49pp |
| 2014-12-31 | 22.97% | $1.95 Million | $8.47 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $4.05 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.34 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.12 Million | -- |
| 2009-12-31 | 8.92% | $199.61K | $2.24 Million | +3.02pp |
| 2008-12-31 | 5.89% | $199.61K | $3.39 Million | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more